13.05.2011 • NewsMomentiveBilanzHexion

Momentive Reports Strong Q1

Momentive Specialty Chemicals  (formerly Hexion Specialty Chemicals) has reported revenues of $1.4 billion Q1 2011, compared to $1.1 billion during the prior year period as sales continued to increase primarily due to volume gains and pricing actions including the contractual pass through of higher raw material costs. The company had an operating income of $120 million, compared to operating income of $63 million for the prior year period.

The Q1 2011 operating income rose significantly compared to the prior year due to higher volumes, improving margins and ongoing cost productivity programs. The company has also posted a net income of $63 million for the first quarter of 2011 versus net loss of $7 million in the prior year period. The Q1 2011 results reflected the same factors impacting operating income.

Segment EBITDA (earnings before interest, taxes, depreciation and amortization) totaled $180 million in the first quarter of 2011 compared to $116 million during the prior year period. In addition, the Momentive reported pro forma adjusted EBITDA for the last 12 months of $747 million, including savings of approximately $48 million that the company expects to achieve in connection with the shared services agreement that it entered into with MPM.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.

Photo
08.11.2024 • News

Future Prospects in Green Chemistry

The Discourse on Green Chemistry Interactive Pitch Competition, held on November 5, 2024, at Wiley's Berlin office as part of Berlin Science Week, showcased a range of innovative projects aimed at addressing critical environmental challenges.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.